Hims & Hers Health reported a near 50% year-over-year revenue increase in the third quarter of fiscal 2025, lifting top-line sales to approximately $600 million. Average revenue per user (ARPU) also climbed, reflecting stronger customer engagement and higher-value offerings. Despite a gross margin decline to roughly 74%—down from the high-70s range due to shifts in GLP-1 shipping cadence, strategic price reductions and inefficiencies from recent facility expansions—the company generated $79 million in free cash flow for the quarter. Operating cash flow approached $150 million, driving the firm’s cash and marketable securities balance to exceed $1 billion. This robust liquidity position underpins ongoing reinvestment in product development and supports share repurchase programs, bolstering long-term financial flexibility.

Building on its digital-first model, Hims & Hers is scaling its platform with a suite of diagnostic offerings, artificial intelligence-driven treatment recommendations and specialty therapies designed to deliver personalized health solutions. The company has introduced at-home lab testing kits for key biomarkers, integrated AI algorithms that analyze patient data to optimize treatment regimens, and expanded its telehealth network to include board-certified specialists in dermatology, mental health and women’s hormone therapy. These enhancements aim to increase customer lifetime value by offering end-to-end continuity of care, reducing referral friction and differentiating Hims & Hers from traditional telemedicine providers. Early pilot results show a 15% uptick in patient adherence rates for chronic condition management programs.